A phase II study of single agent paclitaxel in patients at first relapse following initial chemotherapy for breast cancer

Davidson, N.; Chick, Jon; Perren, Timothy J.; Campbell, Nikki; Thompson, J. M.; Chan, Ya-Ning

doi:10.1016/s0936-6555(96)80077-x

Cited by 4 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fifteen articles reported proportions for arthralgia and myalgia as separate categories, 4,9,[13][14][15][16]18,19,21,23,33,34,36,37,47 while 23 articles documented them jointly as a single category either as a percentage encapsulating ''arthralgia and myalgia,'' ''arthralgia or myalgia,'' or ''arthralgia and/ or myalgia.'' [5][6][7][8][10][11][12]17,20,22,[24][25][26][27][28][29][30][31][32][34][35][36][37][38][39] World Health Organization (WHO) grades of arthralgia and myalgia incorporated in the percentages were not consistent between each article.…”

Section: Discussionmentioning

confidence: 99%

“…Sixteen articles, comprising a total of 7744 patients, reported incidences of <25% for the categories ''arthralgia and myalgia,'' ''arthralgia or myalgia,'' ''arthralgia and/or myalgia,'' or both toxicities separately; 5,7,11,17,19,[23][24][25][26][27][28][29][30][31][32][33][34][35][28][29][30][31][32]34,36,38 10 articles, comprising a total of 1099 patients, reported incidences between 25% and 49%; 8,10,18,[20][21][22]26,27,35,39 two articles, with a total of 1173 patients, reported incidences between 50% and 74%; 6,12 and zero reported incidences of >75%. Seven articles reported incidences for arthralgia and myalgia separately that fit into different quartiles and thus could not be grouped definitively in the specific categories of <25%, 25%-49%, 50%-74%, or >75%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Taxane-induced arthralgia and myalgia: A literature review

Chiu

Chow

et al. 2016

J Oncol Pharm Pract

View full text Add to dashboard Cite

Purpose Arthralgia and myalgia following taxane chemotherapy has been documented in the literature. However, these two toxicities associated with taxane treatment have not been closely examined in the literature, and data remain inconsistent in terms of the reported incidences of these toxicities. The purpose of this literature review was to provide a more comprehensive understanding of the incidence of taxane-induced arthralgia and myalgia, as well as to document the risk factors and preventative and therapeutic treatments that have been investigated. Methods A literature search was conducted in Ovid Medline, OldMedline, Embase, Embase Classic, and Cochrane Central Register of Controlled Trials using relevant subject headings and keywords such as: "arthralgia," "myalgia," "muscle pain," "joint pain," "taxane," "chemotherapy," "docetaxel," "paclitaxel." Results The reported incidences of arthralgia and myalgia were variable. Taxane chemotherapy was found to be associated with greater incidences of arthralgia and myalgia than non-taxane forms of chemotherapy. Moreover, docetaxel and nab-paclitaxel seem to be associated with lower incidences of arthralgia and myalgia than paclitaxel. Finally, the literature on prevention and therapeutic treatment of taxane-induced arthralgia and myalgia is scarce. Conclusion More studies should be done in order to more conclusively identify optimal therapeutic and preventative treatments as well as different risk factors. We recommend that a prospective study be done in order to better understand the true incidence of arthralgia and myalgia in patients being treated with the paclitaxel, docetaxel, and nab-paclitaxel.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Taxane-induced arthralgia and myalgia: A literature review

Chiu

Chow

et al. 2016

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…Paclitaxel is an effective agent in the treatment of metastatic breast cancer. In phase II and III trials where paclitaxel has been given every third week at doses of 135–250 mg/m 2 administered by 3-hour or 24-hour infusion, response rates of 23–60% have been reported [3–7]. The activity and tolerability of weekly dosing of paclitaxel have attracted much interest.…”

Section: Introductionmentioning

confidence: 99%

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer

Wist

Mjaaland

Løkkevik

et al. 2012

Journal of Oncology

View full text Add to dashboard Cite

Background. We performed a randomized phase II study comparing efficacy and toxicity of weekly paclitaxel 80 mg/m2 (Weetax) with three weekly docetaxel 75 mg/m2 (Threetax), both in combination with oral capecitabine 1000 mg/m2 twice daily for 2 weeks followed by a 1-week break. Patients. Thirty-seven women with confirmed metastatic breast cancer were randomized. Results. Median TTF was 174 (Weetax) versus 147 days (Threetax) (P=0.472). Median OS was 933 (Weetax) versus 464 days (Threetax) (P=0.191). Reasons for TTF were PD 8/18 (Weetax), 9/19 (Threetax); and toxicity: 8/18 (Weetax), 8/19 (Threetax). ORR was 72% (Weetax) versus 26% (Threetax) (P = 0.01). The Threetax-combination resulted in a higher incidence of leuco-/neutropenia compared to Weetax. Grade II anemia was more pronounced in the Weetax group. No difference was found in quality of life. Conclusion. Taxanes in combination with capecitabine resulted in a high level of toxicity. Taxanes and capecitabine should be considered given sequentially and not in combination.

show abstract